BMO Capital Maintains Market Perform Rating on Bristol-Myers (BMY) After Earnings Beat

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the best retirement stocks to buy now. On May 4, BMO Capital restated its Market Perform rating for Bristol-Myers Squibb Company (NYSE:BMY) while keeping a $60 price target on the company’s shares. The firm stated that near-term clinical results will affect market assumptions post-legacy product loss of exclusivity incidents.

The rating came after Bristol-Myers Squibb’s first-quarter revenue and earnings exceeded analyst projections. The company’s EPS of $1.58 exceeded market projections of $1.42, while its revenue of $11.49 billion crossed the consensus estimate of $10.92 billion. Year-over-year, total revenue increased by 3%, or 1% when currency effects are ruled out.

The company’s Growth Portfolio earned $6.2 billion, up 12%, primarily driven by Camzyos, Breyanzi, and Reblozyl.

BMO Capital now forecasts 2026 revenue of $16.4 billion, up from $16.1 billion previously, indicating slower depreciation. That said, the company’s pipeline to bridge revenues is under some pressure due to the generic entry of Revlimid and Pomalyst, Eliquis’ loss of exclusivity, and losses in IRA-related revenue.

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious diseases, including cancer, blood disorders, immune conditions, cardiovascular disease, and neurological disorders.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Follow Insider Monkey on Google News.